NAZIM AYDIN

Dr. NAZIM AYDIN

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
GMGozde Mutevelizade
Gozde Mutevelizade
BBBilal Cagri Bozdemir
Bilal Cagri Bozdemir
NANAZIM AYDIN
NAZIM AYDIN
ESElvan Sayit
Elvan Sayit
Background/Objectives: The aim of this study was to investigate the relationship between the PRIMARY score derived from [68Ga]Ga-PSMA PET/CT and key clinical and pathological parameters of prostate cancer aggressiveness, including the PSA level, ISUP Grade Group, and D’Amico risk classification, in patients with biopsy-proven prostate cancer. A secondary aim was to evaluate the interobserver agreement of the PRIMARY score in routine clinical practice. Methods: This retrospective analysis included 51 patients with histopathologically confirmed prostate adenocarcinoma who underwent [68Ga]Ga-PSMA PET/CT imaging for staging. PRIMARY scores were determined based on the intraprostatic uptake pattern, intensity, and zonal localization. These scores were compared with PSA levels, ISUP GG, D’Amico risk classification, and histopathological features such as the cribriform pattern, intraductal carcinoma, perineural invasion, extraprostatic extension, and lymphovascular invasion. The PRIMARY scores were independently assigned by a total of three nuclear medicine physicians, and interobserver agreement was calculated using Fleiss’ kappa analysis. Results: Significant associations were found between the PRIMARY scores and the PSA level, ISUP Grade Group, and D’Amico risk classification. The most prevalent score was PRIMARY 5 (54.9%), which was significantly associated with ISUP GG 5 and the high-risk category in D’Amico classification. Among patients with PRIMARY Score 2, a substantial proportion (64.7%) had ISUP GG ≥ 3, and 58.8% were in the high-risk group, highlighting the limitations of binary PRIMARY classification. No statistically significant correlations were found between the PRIMARY scores and specific histopathologic features. Interobserver agreement was excellent (κ = 0.833). Conclusions: The PRIMARY score demonstrates high reproducibility and clinical relevance in stratifying prostate cancer aggressiveness. However, the findings challenge the reliability of binary classifications, particularly for patients with Score 2, who may still harbor high-grade disease. Integrating imaging-based scores with clinical and histopathological data is essential, particularly for accurate staging and decision-making regarding active surveillance.

8 October 2025 in Molecular Imaging and Radionuclide Therapy
Verified
Journal Article
Open access
PDF file
GMGozde Mutevelizade
Gozde Mutevelizade
BBBilal Çağrı Bozdemir
Bilal Çağrı Bozdemir
NANAZIM AYDIN
NAZIM AYDIN
ASAhmet Furkan Süner
Ahmet Furkan Süner
ÖÇÖmür Karakoyun Çelik
Ömür Karakoyun Çelik
ESElvan Sayıt
Elvan Sayıt
Radiation-induced Xerostomia: Evaluation with 18F-FDG PET/CT - Molecular Imaging and Radionuclide Therapy

18 August 2025 in Molecular Oncologic Imaging
Verified
Journal Article
Closed access
GMGozde Mutevelizade
Gozde Mutevelizade
NANAZIM AYDIN
NAZIM AYDIN
AEATIKE PINAR ERDOGAN
ATIKE PINAR ERDOGAN
BBBilal Cagri Bozdemir
Bilal Cagri Bozdemir
NKNagihan KOLKIRAN
Nagihan KOLKIRAN
ESElvan S.BIlgin
Elvan S.BIlgin
Objective: This study aimed to assess the prognostic significance of 18F-FDG PET/CT metabolic parameters in patients with non-small cell lung cancer (NSCLC) receiving nivolumab as second-line therapy. The study also explored associations between these parameters, treatment response, and survival outcomes. Methods: A retrospective analysis was performed on 32 stage IV NSCLC patients who received at least four doses of nivolumab and underwent both baseline and follow-up PET/CT scans. Metabolic parameters, including SUVmax, SUVmean, total metabolic tumor volume (tMTV), and total lesion glycolysis (tTLG), were measured. Treatment response was classified according to EORTC criteria. Kaplan–Meier analysis and log-rank tests were applied for survival comparisons, and non-parametric methods evaluate associations. Results: Patients with partial metabolic response demonstrated significantly longer post-nivolumab survival. Post-treatment SUVmax, SUVmean, and tTLG differed significantly among response categories. Pretreatment tMTV and tTLG, and post-treatment SUVmax, SUVmean, and tTLG, were significantly associated with mortality (p